About Catabasis Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -0.68$ per share.

The book value per share is 0.64$

Catabasis Pharmaceuticals, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -26M - -25M -0.68 - - 39M 0.64 -24M - -24M